Rationalizing the development of live attenuated virus vaccines

Nature Biotechnology
Adam S LauringRaul Andino


The design of vaccines against viral disease has evolved considerably over the past 50 years. Live attenuated viruses (LAVs)-those created by passaging a virus in cultured cells-have proven to be an effective means for preventing many viral diseases, including smallpox, polio, measles, mumps and yellow fever. Even so, empirical attenuation is unreliable in some cases and LAVs pose several safety issues. Although inactivated viruses and subunit vaccines alleviate many of these concerns, they have in general been less efficacious than their LAV counterparts. Advances in molecular virology--creating deleterious gene mutations, altering replication fidelity, deoptimizing codons and exerting control by microRNAs or zinc finger nucleases--are providing new ways of controlling viral replication and virulence and renewing interest in LAV vaccines. Whereas these rationally attenuated viruses may lead to a new generation of safer, more widely applicable LAV vaccines, each approach requires further testing before progression to human testing.


Sep 17, 1977·British Medical Journal·J Salk
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D Panicali, E Paoletti
Mar 26, 1982·Science·J HollandS VandePol
Jan 10, 1981·Nucleic Acids Research·R GranthamR Mercier
Mar 18, 1999·Journal of Molecular Evolution·C R Stephens, H Waelbroeck
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·X J Da CostaD M Knipe
May 22, 2001·Cellular and Molecular Life Sciences : CMLS·S Iuchi
Dec 26, 2001·Journal of Virology·Tokiko WatanabeYoshihiro Kawaoka
May 15, 2002·Current Biology : CB·Mariana Lagos-QuintanaThomas Tuschl
Jul 20, 2002·Seminars in Cell & Developmental Biology·Zhou ZhuJack A Elias
Jan 28, 2003·Vaccine·Gideon F A Kersten, Daan J A Crommelin
Feb 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·Monika PapworthAaron Klug
Feb 28, 2003·Virus Research·Gareth M Jenkins, Edward C Holmes
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Joshua B Plotkin, Jonathan Dushoff
May 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Julie K Pfeiffer, Karla Kirkegaard
Jul 13, 2004·Trends in Biotechnology·Claes GustafssonJeremy Minshull
Nov 25, 2004·Current Opinion in Biotechnology·Diana FelnerovaChristian Moser
Jan 15, 2005·Virus Research·Christof K Biebricher, Manfred Eigen
May 10, 2005·The Journal of Biological Chemistry·Jamie J ArnoldCraig E Cameron
Jul 27, 2005·Biochemical and Biophysical Research Communications·Mala ManiSrinivasan Chandrasegaran
Oct 13, 2005·PLoS Pathogens·Julie K Pfeiffer, Karla Kirkegaard
Dec 21, 2005·Virology·Tim Dudek, David M Knipe
Dec 21, 2005·Virology·Ann M Arvin, Harry B Greenberg
Jan 18, 2006·Accounts of Chemical Research·Muthu DhanasekaranYukio Sugiura
Mar 25, 2006·Journal of Molecular Evolution·Laura A ShackeltonEdward C Holmes
Dec 11, 2007·Nature Biotechnology·Joost HaasnootBen Berkhout
Feb 5, 2008·Nature Medicine·Marco VignuzziRaul Andino
Feb 21, 2008·Journal of Molecular Evolution·Alessandra Carbone
Mar 29, 2008·Methods in Molecular Biology·Matthew Porteus
May 10, 2008·Science·Bruce D Walker, Dennis R Burton
Jun 11, 2008·Cell Host & Microbe·Eva Gottwein, Bryan R Cullen
Jun 28, 2008·Science·J Robert ColemanSteffen Mueller
Jul 8, 2008·Vaccine·Robert B Couch

❮ Previous
Next ❯


Feb 8, 2013·The New England Journal of Medicine·Gary J Nabel
Aug 3, 2012·The Journal of Biological Chemistry·Spencer A WeeksCraig E Cameron
Mar 23, 2012·Journal of Virology·Elizabeth G KurthValerian V Dolja
Dec 3, 2010·Journal of Virology·Brian L HeissAlexander G Pletnev
Feb 15, 2011·Veterinary Research·Stéphane Biacchesi
Nov 12, 2010·Immunome Research·Samuel Ojosnegros, Niko Beerenwinkel
Oct 8, 2013·PloS One·Yo Han JangBaik Lin Seong
Dec 4, 2012·Viruses·Igor S Lukashevich
Jul 25, 2012·Therapeutic Delivery·Regina Scherliess
Nov 5, 2013·AIDS Research and Human Retroviruses·Sarah B LloydWendy R Winnall
Aug 23, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter A Patriarca
Jun 24, 2014·Cell Reports·Simone BackesBenjamin R tenOever
Jan 23, 2016·Antiviral Research·Natalya L TeterinaAlexander G Pletnev
Oct 13, 2011·Expert Review of Vaccines·Michael W Wolf, Udo Reichl
Dec 22, 2012·Expert Review of Vaccines·Igor S Lukashevich
Oct 2, 2015·Science Translational Medicine·Christopher J A DuncanSophie Hambleton
Jun 23, 2012·Antiviral Research·Frederick S B KibengeMolly J T Kibenge
Jan 24, 2012·Vaccine·Manon M J Cox
Apr 6, 2016·Regenerative Biomaterials·Ling LiYu-Quan Wei
Oct 2, 2012·Tissue Antigens·B Gentner, L Naldini
Jul 28, 2012·Current Opinion in Virology·Sara L Sawyer, Nels C Elde
Apr 1, 2015·Future Microbiology·Ananda S BandyopadhyayWalter A Orenstein
Jul 7, 2016·Proceedings of the National Academy of Sciences of the United States of America·Jasdave S ChahalDaniel G Anderson
Nov 1, 2016·Proceedings. Biological Sciences·Scott L NuismerRustom Antia
Nov 11, 2016·Future Microbiology·Radboud J Duintjer Tebbens, Kimberly M Thompson
Nov 14, 2017·Viral Immunology·Stanley A Plotkin
Apr 28, 2018·PLoS Biology·Michael FamulareGuillaume Chabot-Couture
Aug 12, 2017·International Reviews of Immunology·Jonathon KeckBernard P Arulanandam
May 27, 2016·World Journal of Experimental Medicine·Anja Geisler, Henry Fechner
Jun 22, 2018·Journal of Virology·Ekaterina G ViktorovaGeorge A Belov
Dec 15, 2015·Journal of Virology·Mélissanne de WispelaereNathalie Pardigon

❮ Previous
Next ❯

Methods Mentioned


Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.